APOE and Alzheimer disease: Accordingly, female APOE4 carriers showed hypometabolism and cortical thinning with respect to non-carriers, suggesting that female APOE4 carriers might be more advanced in the aforementioned 2-phase phenomenon model in preclinical AD [28].